Study on 198 patients with HIV diagnosed following the criteria of Department of Health at the Infectious Department of Hospital No.103, including 55 HIV/HCV coinfection patients, by retrospective and prospective research
The authors divided patients into two groups to treat with two different drug combinations and compare the change of hepatic enzymes, bilirubin between them. The result as follows: - In the HIV/HCV coinfection group treated with d4T/3TC/EFV, the rate of the patients having an increase in hepatic enzymes were decreased with duration of treatment
- In the group treated with NVP (d4T/3TC/NVP), after 4 weeks of treatment, it made a rise in rate of the patients having the increased hepatic enzymes. Among them this rate of the HIV/HCV coinfection group was significant higher than the monoinfection (ALT: 28.9 percent and AST: 28.9 percent of the HIV/HCV coinfection group compared with ALT: 11.1 percent and AST: 12.1 percent of the monoinfection group).